JP2006500009A - 腫瘍の診断と治療のための組成物と方法 - Google Patents

腫瘍の診断と治療のための組成物と方法 Download PDF

Info

Publication number
JP2006500009A
JP2006500009A JP2004520117A JP2004520117A JP2006500009A JP 2006500009 A JP2006500009 A JP 2006500009A JP 2004520117 A JP2004520117 A JP 2004520117A JP 2004520117 A JP2004520117 A JP 2004520117A JP 2006500009 A JP2006500009 A JP 2006500009A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
polypeptide
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004520117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006500009A5 (https=
Inventor
ハイデ， エス． フィリップス，
ユー−ジュ， ジー． メン，
リチャード， エル． バンドレン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2006500009A publication Critical patent/JP2006500009A/ja
Publication of JP2006500009A5 publication Critical patent/JP2006500009A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Testing Resistance To Weather, Investigating Materials By Mechanical Methods (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004520117A 2002-07-09 2003-07-08 腫瘍の診断と治療のための組成物と方法 Withdrawn JP2006500009A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39499802P 2002-07-09 2002-07-09
PCT/US2003/021606 WO2004004662A2 (en) 2002-07-09 2003-07-08 Compositions and methods for the diagnosis and treatment of tumor

Publications (2)

Publication Number Publication Date
JP2006500009A true JP2006500009A (ja) 2006-01-05
JP2006500009A5 JP2006500009A5 (https=) 2006-08-24

Family

ID=30115799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004520117A Withdrawn JP2006500009A (ja) 2002-07-09 2003-07-08 腫瘍の診断と治療のための組成物と方法

Country Status (7)

Country Link
US (2) US20060062727A1 (https=)
EP (1) EP1572091A4 (https=)
JP (1) JP2006500009A (https=)
AU (1) AU2003249014B2 (https=)
CA (1) CA2491488A1 (https=)
IL (1) IL165950A0 (https=)
WO (1) WO2004004662A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512407A (ja) * 2002-09-27 2006-04-13 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
JP2007525443A (ja) * 2003-05-02 2007-09-06 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
WO2009087978A1 (ja) * 2008-01-11 2009-07-16 The University Of Tokyo 抗cldn6抗体
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US12528863B2 (en) 2019-07-10 2026-01-20 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
EP3873519A1 (en) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antibody formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155335C (en) * 1993-02-04 2001-06-05 HANS CHRISTIAN THõGERSEN Improved method for the refolding of proteins
IT1318691B1 (it) * 2000-09-12 2003-08-27 Consiglio Nazionale Ricerche Varianti di proteine allergeniche del gruppo 2 di dermatophagoides.
US7341721B2 (en) * 2002-04-12 2008-03-11 The Board Of Trustees Of The University Of Arkansas β2-microglobulin (β2m) and anti-β2m binding agents as anti-cancer therapeutics

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512407A (ja) * 2002-09-27 2006-04-13 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
JP2007525443A (ja) * 2003-05-02 2007-09-06 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
WO2009087978A1 (ja) * 2008-01-11 2009-07-16 The University Of Tokyo 抗cldn6抗体
JPWO2009087978A1 (ja) * 2008-01-11 2011-05-26 国立大学法人 東京大学 抗ｃｌｄｎ６抗体
US9274119B2 (en) 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US12528863B2 (en) 2019-07-10 2026-01-20 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof

Also Published As

Publication number Publication date
US20060062727A1 (en) 2006-03-23
AU2003249014B2 (en) 2009-07-02
US20090181014A1 (en) 2009-07-16
WO2004004662A2 (en) 2004-01-15
EP1572091A4 (en) 2008-03-05
WO2004004662A3 (en) 2005-08-11
IL165950A0 (en) 2006-01-15
EP1572091A2 (en) 2005-09-14
AU2003249014A1 (en) 2004-01-23
CA2491488A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
JP4822710B2 (ja) 腫瘍の診断と治療のための組成物と方法
US7514538B2 (en) Compositions and methods for the diagnosis and treatment of tumor
JP5587841B2 (ja) 造血系起源の腫瘍の治療のための組成物と方法
JP2006500009A (ja) 腫瘍の診断と治療のための組成物と方法
JP4703567B2 (ja) 膠細胞起源の腫瘍の診断と治療のための組成物と方法
EP1445318A2 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2006516089A (ja) 腫瘍の診断と治療のための組成物と方法
JP2005536190A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006510735A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516192A (ja) 腫瘍の診断と治療のための組成物と方法
JP2008137989A (ja) 腫瘍の診断と治療のための組成物と方法
JP2012046515A (ja) 腫瘍の診断と治療のための組成物と方法
JP2005528905A (ja) 腫瘍の診断と治療のための組成物と方法
US8097700B2 (en) TAT294 polypeptides
JP2004520810A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007521791A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007077155A (ja) 腫瘍の診断と治療のための組成物と方法
JP2004520808A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516655A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007512019A (ja) 腫瘍の診断と治療のための組成物と方法
US20050159588A1 (en) Compositions and methods for the diagnosis and treatment of tumor
KR100607610B1 (ko) 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20070031901A1 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2005523311A (ja) 腫瘍の診断と治療のための組成物と方法
JP2005513084A (ja) 腫瘍の診断と治療のための組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060707

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090730